A Rapid Clinical Care Pathway to Care for Patients Affected by Chronic Constipation
Completed · Not applicable · NCT07032376
Conditions: Constipation
At a glance
- Research payments reported, 2025
- $2,360
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 49
About the trial
- Sponsor
- University of Michigan (with National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK))
- Tested
- Survey (behavioral), Rectal Expulsion Device use (behavioral)
- Dates
- Started 2025-08-20; completion 2026-09-04
- Results posted
- Not yet
This research is studying how the availability of a Food and Drug Administration (FDA)-cleared point-of-care, bedside device bedside device called Rectal Expulsion Device (RED) can be used to evaluate constipation in the participants' routine office visit with the participants' care provider. In this research, participants will be asked to complete a survey prior to the gastroenterology office consultation. Health-related information will be collected for this research study. There are no additional study visits for this research study.
From ClinicalTrials.gov, last updated 2026-09-25. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Neuraxis, Inc. reported $2,360 in research payments for this study in 2025 (1 payments).
Products named: Red
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.